CN1335849A - 作为蛋白激酶抑制剂的吡咯并嘧啶 - Google Patents

作为蛋白激酶抑制剂的吡咯并嘧啶 Download PDF

Info

Publication number: CN1335849A
Authority: CN; China
Prior art keywords: unsubstituted; replace; pyrrolo; amino; pyrimidin
Prior art date: 1998-09-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN99813217A

Other languages

English (en)

Chinese (zh)

Inventor

G·C·赫斯特

D·克莱德伍德

N·威沙特

K·里特尔

L·D·阿诺德

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ebert GmbH and Co KG

Original Assignee

BASF SE

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-18

Filing date

1999-09-17

Publication date

2002-02-13

1999-09-17 Application filed by BASF SE filed Critical BASF SE

2002-02-13 Publication of CN1335849A publication Critical patent/CN1335849A/zh

Status Pending legal-status Critical Current

Links

229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
239000003909 protein kinase inhibitor Substances 0.000 title 1
150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 251
238000000034 method Methods 0.000 claims abstract description 100
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 82
201000010099 disease Diseases 0.000 claims abstract description 70
230000000694 effects Effects 0.000 claims abstract description 58
150000003839 salts Chemical class 0.000 claims abstract description 56
102000001253 Protein Kinase Human genes 0.000 claims abstract description 43
108060006633 protein kinase Proteins 0.000 claims abstract description 43
102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims abstract description 39
108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims abstract description 39
206010028980 Neoplasm Diseases 0.000 claims abstract description 38
201000011510 cancer Diseases 0.000 claims abstract description 26
230000033115 angiogenesis Effects 0.000 claims abstract description 12
239000002207 metabolite Substances 0.000 claims abstract description 7
206010052779 Transplant rejections Diseases 0.000 claims abstract description 6
-1 alkyl sulfone Chemical class 0.000 claims description 257
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 139
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 132
125000003118 aryl group Chemical group 0.000 claims description 128
125000000217 alkyl group Chemical group 0.000 claims description 93
125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 92
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 86
150000001412 amines Chemical class 0.000 claims description 65
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 63
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 61
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 57
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 56
238000002360 preparation method Methods 0.000 claims description 51
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 50
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 50
229910052739 hydrogen Inorganic materials 0.000 claims description 48
239000001257 hydrogen Substances 0.000 claims description 48
125000001931 aliphatic group Chemical group 0.000 claims description 41
125000003710 aryl alkyl group Chemical group 0.000 claims description 41
108091000080 Phosphotransferase Proteins 0.000 claims description 40
125000004433 nitrogen atom Chemical group N* 0.000 claims description 40
102000020233 phosphotransferase Human genes 0.000 claims description 40
210000004204 blood vessel Anatomy 0.000 claims description 39
238000006243 chemical reaction Methods 0.000 claims description 39
125000001072 heteroaryl group Chemical group 0.000 claims description 39
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 39
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 34
230000004862 vasculogenesis Effects 0.000 claims description 34
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 30
101100481410 Mus musculus Tek gene Proteins 0.000 claims description 29
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 29
206010030113 Oedema Diseases 0.000 claims description 28
101100481408 Danio rerio tie2 gene Proteins 0.000 claims description 27
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 27
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 26
206010020852 Hypertonia Diseases 0.000 claims description 25
101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims description 23
101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims description 23
125000004093 cyano group Chemical group *C#N 0.000 claims description 22
OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 claims description 20
150000002431 hydrogen Chemical class 0.000 claims description 19
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 18
125000000753 cycloalkyl group Chemical group 0.000 claims description 18
230000001404 mediated effect Effects 0.000 claims description 18
230000004913 activation Effects 0.000 claims description 17
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 16
210000004291 uterus Anatomy 0.000 claims description 16
230000002062 proliferating effect Effects 0.000 claims description 14
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 14
125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 14
125000001424 substituent group Chemical group 0.000 claims description 14
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 13
239000000126 substance Substances 0.000 claims description 13
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 claims description 12
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 claims description 12
239000002253 acid Substances 0.000 claims description 12
125000004475 heteroaralkyl group Chemical group 0.000 claims description 12
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 12
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 10
206010061218 Inflammation Diseases 0.000 claims description 10
230000004054 inflammatory process Effects 0.000 claims description 10
125000001544 thienyl group Chemical group 0.000 claims description 10
101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims description 9
102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 9
108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 9
229910052801 chlorine Inorganic materials 0.000 claims description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 8
102100040681 Platelet-derived growth factor C Human genes 0.000 claims description 8
208000025865 Ulcer Diseases 0.000 claims description 8
BFAKENXZKHGIGE-UHFFFAOYSA-N bis(2,3,5,6-tetrafluoro-4-iodophenyl)diazene Chemical compound FC1=C(C(=C(C(=C1F)I)F)F)N=NC1=C(C(=C(C(=C1F)F)I)F)F BFAKENXZKHGIGE-UHFFFAOYSA-N 0.000 claims description 8
229910052794 bromium Inorganic materials 0.000 claims description 8
229910052731 fluorine Inorganic materials 0.000 claims description 8
229910052740 iodine Inorganic materials 0.000 claims description 8
108010017992 platelet-derived growth factor C Proteins 0.000 claims description 8
230000001225 therapeutic effect Effects 0.000 claims description 8
231100000397 ulcer Toxicity 0.000 claims description 8
102100022014 Angiopoietin-1 receptor Human genes 0.000 claims description 7
206010003445 Ascites Diseases 0.000 claims description 7
206010003497 Asphyxia Diseases 0.000 claims description 7
206010016654 Fibrosis Diseases 0.000 claims description 7
101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 claims description 7
201000004681 Psoriasis Diseases 0.000 claims description 7
208000027418 Wounds and injury Diseases 0.000 claims description 7
125000004103 aminoalkyl group Chemical group 0.000 claims description 7
229910052799 carbon Inorganic materials 0.000 claims description 7
125000004432 carbon atom Chemical group C* 0.000 claims description 7
239000003102 growth factor Substances 0.000 claims description 7
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
125000005504 styryl group Chemical group 0.000 claims description 7
BVMWIXWOIGJRGE-UHFFFAOYSA-N NP(O)=O Chemical compound NP(O)=O BVMWIXWOIGJRGE-UHFFFAOYSA-N 0.000 claims description 6
208000017442 Retinal disease Diseases 0.000 claims description 6
206010038923 Retinopathy Diseases 0.000 claims description 6
108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims description 6
206010052428 Wound Diseases 0.000 claims description 6
230000000975 bioactive effect Effects 0.000 claims description 6
125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 6
150000002460 imidazoles Chemical class 0.000 claims description 6
150000002475 indoles Chemical class 0.000 claims description 6
125000002971 oxazolyl group Chemical group 0.000 claims description 6
125000004076 pyridyl group Chemical group 0.000 claims description 6
230000004044 response Effects 0.000 claims description 6
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
230000001684 chronic effect Effects 0.000 claims description 5
206010012601 diabetes mellitus Diseases 0.000 claims description 5
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 5
125000001624 naphthyl group Chemical group 0.000 claims description 5
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
208000037803 restenosis Diseases 0.000 claims description 5
IEKBSYUNNVXOCB-UHFFFAOYSA-N 4-chloro-2,1,3-benzothiadiazole Chemical compound ClC1=CC=CC2=NSN=C12 IEKBSYUNNVXOCB-UHFFFAOYSA-N 0.000 claims description 4
IYZKISWGGPKREZ-UHFFFAOYSA-N 4-methyl-2,1,3-benzothiadiazole Chemical compound CC1=CC=CC2=NSN=C12 IYZKISWGGPKREZ-UHFFFAOYSA-N 0.000 claims description 4
VRNJWKISMWDTAY-UHFFFAOYSA-N 5-chloro-2,1,3-benzothiadiazole Chemical compound C1=C(Cl)C=CC2=NSN=C21 VRNJWKISMWDTAY-UHFFFAOYSA-N 0.000 claims description 4
XDQJAYFCPRWDOL-UHFFFAOYSA-N 5-methyl-2,1,3-benzothiadiazole Chemical compound C1=C(C)C=CC2=NSN=C21 XDQJAYFCPRWDOL-UHFFFAOYSA-N 0.000 claims description 4
201000001320 Atherosclerosis Diseases 0.000 claims description 4
206010048962 Brain oedema Diseases 0.000 claims description 4
208000011231 Crohn disease Diseases 0.000 claims description 4
206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
208000004232 Enteritis Diseases 0.000 claims description 4
XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 claims description 4
241000233866 Fungi Species 0.000 claims description 4
208000010412 Glaucoma Diseases 0.000 claims description 4
208000001344 Macular Edema Diseases 0.000 claims description 4
206010025415 Macular oedema Diseases 0.000 claims description 4
206010039491 Sarcoma Diseases 0.000 claims description 4
206010040047 Sepsis Diseases 0.000 claims description 4
125000003282 alkyl amino group Chemical group 0.000 claims description 4
125000001118 alkylidene group Chemical group 0.000 claims description 4
208000007502 anemia Diseases 0.000 claims description 4
125000005129 aryl carbonyl group Chemical group 0.000 claims description 4
125000004657 aryl sulfonyl amino group Chemical group 0.000 claims description 4
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 4
208000006752 brain edema Diseases 0.000 claims description 4
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
230000004761 fibrosis Effects 0.000 claims description 4
239000003205 fragrance Substances 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
208000032839 leukemia Diseases 0.000 claims description 4
201000010230 macular retinal edema Diseases 0.000 claims description 4
201000006417 multiple sclerosis Diseases 0.000 claims description 4
150000003222 pyridines Chemical class 0.000 claims description 4
230000005855 radiation Effects 0.000 claims description 4
201000003068 rheumatic fever Diseases 0.000 claims description 4
229940124530 sulfonamide Drugs 0.000 claims description 4
208000011580 syndromic disease Diseases 0.000 claims description 4
125000002769 thiazolinyl group Chemical group 0.000 claims description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical class C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 claims description 3
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical class C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 3
108090000328 Arrestin Proteins 0.000 claims description 3
102000003916 Arrestin Human genes 0.000 claims description 3
206010008190 Cerebrovascular accident Diseases 0.000 claims description 3
206010052139 Eye oedema Diseases 0.000 claims description 3
102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims description 3
101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims description 3
206010018364 Glomerulonephritis Diseases 0.000 claims description 3
206010061217 Infestation Diseases 0.000 claims description 3
206010025538 Malignant ascites Diseases 0.000 claims description 3
208000007696 Multicystic Dysplastic Kidney Diseases 0.000 claims description 3
208000010191 Osteitis Deformans Diseases 0.000 claims description 3
206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 claims description 3
208000027868 Paget disease Diseases 0.000 claims description 3
241000700639 Parapoxvirus Species 0.000 claims description 3
206010037423 Pulmonary oedema Diseases 0.000 claims description 3
208000006011 Stroke Diseases 0.000 claims description 3
125000002252 acyl group Chemical group 0.000 claims description 3
125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 3
125000005124 aminocycloalkyl group Chemical group 0.000 claims description 3
125000004181 carboxyalkyl group Chemical group 0.000 claims description 3
230000007882 cirrhosis Effects 0.000 claims description 3
208000019425 cirrhosis of liver Diseases 0.000 claims description 3
OBISXEJSEGNNKL-UHFFFAOYSA-N dinitrogen-n-sulfide Chemical class [N-]=[N+]=S OBISXEJSEGNNKL-UHFFFAOYSA-N 0.000 claims description 3
210000003677 hemocyte Anatomy 0.000 claims description 3
229940000351 hemocyte Drugs 0.000 claims description 3
208000002780 macular degeneration Diseases 0.000 claims description 3
208000027202 mammary Paget disease Diseases 0.000 claims description 3
208000007106 menorrhagia Diseases 0.000 claims description 3
201000011461 pre-eclampsia Diseases 0.000 claims description 3
208000005333 pulmonary edema Diseases 0.000 claims description 3
150000003217 pyrazoles Chemical class 0.000 claims description 3
206010043778 thyroiditis Diseases 0.000 claims description 3
208000006542 von Hippel-Lindau disease Diseases 0.000 claims description 3
CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical class C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 claims description 2
125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims description 2
RLFZYIUUQBHRNV-UHFFFAOYSA-N 2,5-dihydrooxadiazole Chemical compound C1ONN=C1 RLFZYIUUQBHRNV-UHFFFAOYSA-N 0.000 claims description 2
241000894006 Bacteria Species 0.000 claims description 2
208000024172 Cardiovascular disease Diseases 0.000 claims description 2
206010010741 Conjunctivitis Diseases 0.000 claims description 2
206010054044 Diabetic microangiopathy Diseases 0.000 claims description 2
208000019878 Eales disease Diseases 0.000 claims description 2
206010073423 Eye ulcer Diseases 0.000 claims description 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 2
102100021866 Hepatocyte growth factor Human genes 0.000 claims description 2
208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 claims description 2
208000009889 Herpes Simplex Diseases 0.000 claims description 2
208000007514 Herpes zoster Diseases 0.000 claims description 2
241000725303 Human immunodeficiency virus Species 0.000 claims description 2
208000016604 Lyme disease Diseases 0.000 claims description 2
206010025323 Lymphomas Diseases 0.000 claims description 2
208000024599 Mooren ulcer Diseases 0.000 claims description 2
206010029260 Neuroblastoma Diseases 0.000 claims description 2
QMOJXRIOLWCQGL-SPIKMXEPSA-N OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.NS(=O)(=O)C1=CC=CC=C1 Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.NS(=O)(=O)C1=CC=CC=C1 QMOJXRIOLWCQGL-SPIKMXEPSA-N 0.000 claims description 2
206010061876 Obstruction Diseases 0.000 claims description 2
206010034277 Pemphigoid Diseases 0.000 claims description 2
206010038848 Retinal detachment Diseases 0.000 claims description 2
206010039705 Scleritis Diseases 0.000 claims description 2
201000005485 Toxoplasmosis Diseases 0.000 claims description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
206010064996 Ulcerative keratitis Diseases 0.000 claims description 2
206010046851 Uveitis Diseases 0.000 claims description 2
108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims description 2
102100038217 Vascular endothelial growth factor B Human genes 0.000 claims description 2
206010053648 Vascular occlusion Diseases 0.000 claims description 2
206010047663 Vitritis Diseases 0.000 claims description 2
150000005215 alkyl ethers Chemical class 0.000 claims description 2
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
125000005360 alkyl sulfoxide group Chemical group 0.000 claims description 2
125000005012 alkyl thioether group Chemical group 0.000 claims description 2
125000000304 alkynyl group Chemical group 0.000 claims description 2
125000003368 amide group Chemical group 0.000 claims description 2
229940111121 antirheumatic drug quinolines Drugs 0.000 claims description 2
125000001769 aryl amino group Chemical group 0.000 claims description 2
125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 2
125000005362 aryl sulfone group Chemical group 0.000 claims description 2
125000005361 aryl sulfoxide group Chemical group 0.000 claims description 2
150000004832 aryl thioethers Chemical class 0.000 claims description 2
208000006673 asthma Diseases 0.000 claims description 2
JZRUJZYPUJSKOG-UKFGXMPHSA-N benzamide (Z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.NC(=O)c1ccccc1 JZRUJZYPUJSKOG-UKFGXMPHSA-N 0.000 claims description 2
125000000499 benzofuranyl group Chemical class O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
239000012964 benzotriazole Substances 0.000 claims description 2
125000003354 benzotriazolyl group Chemical class N1N=NC2=C1C=CC=C2* 0.000 claims description 2
229910002091 carbon monoxide Inorganic materials 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
210000001715 carotid artery Anatomy 0.000 claims description 2
208000037976 chronic inflammation Diseases 0.000 claims description 2
208000037893 chronic inflammatory disorder Diseases 0.000 claims description 2
125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
201000009101 diabetic angiopathy Diseases 0.000 claims description 2
150000002012 dioxanes Chemical class 0.000 claims description 2
150000004862 dioxolanes Chemical class 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 2
208000013653 hyalitis Diseases 0.000 claims description 2
125000005956 isoquinolyl group Chemical group 0.000 claims description 2
208000001491 myopia Diseases 0.000 claims description 2
230000004379 myopia Effects 0.000 claims description 2
201000008482 osteoarthritis Diseases 0.000 claims description 2
208000008798 osteoma Diseases 0.000 claims description 2
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
125000005554 pyridyloxy group Chemical group 0.000 claims description 2
125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
150000003233 pyrroles Chemical class 0.000 claims description 2
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
230000004264 retinal detachment Effects 0.000 claims description 2
201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims description 2
201000004595 synovitis Diseases 0.000 claims description 2
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
150000003557 thiazoles Chemical class 0.000 claims description 2
125000000335 thiazolyl group Chemical group 0.000 claims description 2
150000003574 thionaphthenes Chemical class 0.000 claims description 2
201000008827 tuberculosis Diseases 0.000 claims description 2
208000021331 vascular occlusion disease Diseases 0.000 claims description 2
229940002612 prodrug Drugs 0.000 claims 5
239000000651 prodrug Substances 0.000 claims 5
150000001408 amides Chemical class 0.000 claims 4
MIODUYDSGXUAGH-DIVCQZSQSA-N COc1cc(ccc1NC(=O)CCc1ccccc1)-c1cn([C@H]2CC[C@@H](CC2)N2CCN(C)CC2)c2ncnc(N)c12 Chemical compound COc1cc(ccc1NC(=O)CCc1ccccc1)-c1cn([C@H]2CC[C@@H](CC2)N2CCN(C)CC2)c2ncnc(N)c12 MIODUYDSGXUAGH-DIVCQZSQSA-N 0.000 claims 2
150000000183 1,3-benzoxazoles Chemical class 0.000 claims 1
230000003844 B-cell-activation Effects 0.000 claims 1
MKFARYZVDAZRLA-HZCBDIJESA-N CN1CCN(CC1)[C@H]1CC[C@@H](CC1)n1cc(-c2ccc(NS(=O)(=O)c3ccc(F)cc3)c(F)c2)c2c(N)ncnc12 Chemical compound CN1CCN(CC1)[C@H]1CC[C@@H](CC1)n1cc(-c2ccc(NS(=O)(=O)c3ccc(F)cc3)c(F)c2)c2c(N)ncnc12 MKFARYZVDAZRLA-HZCBDIJESA-N 0.000 claims 1
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 1
102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 1
208000017604 Hodgkin disease Diseases 0.000 claims 1
208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 1
101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 1
101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 1
102000004877 Insulin Human genes 0.000 claims 1
108090001061 Insulin Proteins 0.000 claims 1
208000007766 Kaposi sarcoma Diseases 0.000 claims 1
208000034578 Multiple myelomas Diseases 0.000 claims 1
206010035226 Plasma cell myeloma Diseases 0.000 claims 1
201000000582 Retinoblastoma Diseases 0.000 claims 1
230000006044 T cell activation Effects 0.000 claims 1
206010043276 Teratoma Diseases 0.000 claims 1
102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 claims 1
102000009519 Vascular Endothelial Growth Factor D Human genes 0.000 claims 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
210000003567 ascitic fluid Anatomy 0.000 claims 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
208000027993 eye symptom Diseases 0.000 claims 1
230000035558 fertility Effects 0.000 claims 1
125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
208000005017 glioblastoma Diseases 0.000 claims 1
201000000289 malignant teratoma Diseases 0.000 claims 1
210000004216 mammary stem cell Anatomy 0.000 claims 1
201000001441 melanoma Diseases 0.000 claims 1
HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
208000010125 myocardial infarction Diseases 0.000 claims 1
RZEVPTBUZBHBMQ-UHFFFAOYSA-N n-[4-[4-amino-7-[1-(pyridine-2-carbonyl)piperidin-4-yl]pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorophenyl]-4-fluorobenzenesulfonamide Chemical compound C1=2C(N)=NC=NC=2N(C2CCN(CC2)C(=O)C=2N=CC=CC=2)C=C1C(C=C1F)=CC=C1NS(=O)(=O)C1=CC=C(F)C=C1 RZEVPTBUZBHBMQ-UHFFFAOYSA-N 0.000 claims 1
150000003248 quinolines Chemical class 0.000 claims 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
239000003112 inhibitor Substances 0.000 abstract description 29
230000008569 process Effects 0.000 abstract description 19
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract description 6
102000009516 Protein Serine-Threonine Kinases Human genes 0.000 abstract description 5
108010009341 Protein Serine-Threonine Kinases Proteins 0.000 abstract description 5
210000002889 endothelial cell Anatomy 0.000 abstract description 4
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract description 3
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract description 3
239000004473 Threonine Substances 0.000 abstract description 3
230000002491 angiogenic effect Effects 0.000 abstract description 3
230000003463 hyperproliferative effect Effects 0.000 abstract description 3
230000001900 immune effect Effects 0.000 abstract description 3
206010039073 rheumatoid arthritis Diseases 0.000 abstract description 2
208000035475 disorder Diseases 0.000 abstract 3
210000000987 immune system Anatomy 0.000 abstract 1
239000000203 mixture Substances 0.000 description 131
239000002585 base Substances 0.000 description 126
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 117
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 97
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 87
239000012071 phase Substances 0.000 description 81
210000004027 cell Anatomy 0.000 description 78
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 62
239000007788 liquid Substances 0.000 description 55
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 52
102100039037 Vascular endothelial growth factor A Human genes 0.000 description 52
239000007787 solid Substances 0.000 description 50
235000002639 sodium chloride Nutrition 0.000 description 49
239000000243 solution Substances 0.000 description 48
QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 44
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 43
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 40
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
235000019439 ethyl acetate Nutrition 0.000 description 39
229940093499 ethyl acetate Drugs 0.000 description 39
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 35
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 34
238000003756 stirring Methods 0.000 description 34
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 30
238000005481 NMR spectroscopy Methods 0.000 description 24
239000003795 chemical substances by application Substances 0.000 description 24
238000001704 evaporation Methods 0.000 description 24
239000000047 product Substances 0.000 description 24
108090000623 proteins and genes Proteins 0.000 description 24
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 22
230000014509 gene expression Effects 0.000 description 22
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 21
102000004169 proteins and genes Human genes 0.000 description 21
235000018102 proteins Nutrition 0.000 description 20
239000000370 acceptor Substances 0.000 description 19
239000003814 drug Substances 0.000 description 19
230000008020 evaporation Effects 0.000 description 19
230000005764 inhibitory process Effects 0.000 description 19
239000011541 reaction mixture Substances 0.000 description 19
238000005406 washing Methods 0.000 description 19
102000004190 Enzymes Human genes 0.000 description 18
108090000790 Enzymes Proteins 0.000 description 18
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 18
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
229940088598 enzyme Drugs 0.000 description 18
229910052757 nitrogen Inorganic materials 0.000 description 18
108091008598 receptor tyrosine kinases Proteins 0.000 description 18
238000012360 testing method Methods 0.000 description 18
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
102000027426 receptor tyrosine kinases Human genes 0.000 description 17
239000000758 substrate Substances 0.000 description 17
238000010586 diagram Methods 0.000 description 16
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 16
241000699666 Mus <mouse, genus> Species 0.000 description 15
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
101150001535 SRC gene Proteins 0.000 description 14
235000019441 ethanol Nutrition 0.000 description 14
239000000706 filtrate Substances 0.000 description 14
239000012530 fluid Substances 0.000 description 14
238000000746 purification Methods 0.000 description 14
150000002148 esters Chemical class 0.000 description 13
238000001914 filtration Methods 0.000 description 13
239000012299 nitrogen atmosphere Substances 0.000 description 13
239000002904 solvent Substances 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 12
108091007914 CDKs Proteins 0.000 description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
238000013016 damping Methods 0.000 description 12
238000003810 ethyl acetate extraction Methods 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
102000003903 Cyclin-dependent kinases Human genes 0.000 description 11
108090000266 Cyclin-dependent kinases Proteins 0.000 description 11
238000002965 ELISA Methods 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
230000008859 change Effects 0.000 description 11
238000005755 formation reaction Methods 0.000 description 11
238000010438 heat treatment Methods 0.000 description 11
239000007924 injection Substances 0.000 description 11
238000002347 injection Methods 0.000 description 11
238000001556 precipitation Methods 0.000 description 11
101150012716 CDK1 gene Proteins 0.000 description 10
241001465754 Metazoa Species 0.000 description 10
239000012044 organic layer Substances 0.000 description 10
239000008194 pharmaceutical composition Substances 0.000 description 10
230000026731 phosphorylation Effects 0.000 description 10
238000006366 phosphorylation reaction Methods 0.000 description 10
238000010898 silica gel chromatography Methods 0.000 description 10
101100464293 Caenorhabditis elegans plk-1 gene Proteins 0.000 description 9
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
210000001744 T-lymphocyte Anatomy 0.000 description 9
229910000147 aluminium phosphate Inorganic materials 0.000 description 9
239000006185 dispersion Substances 0.000 description 9
238000000605 extraction Methods 0.000 description 9
206010020718 hyperplasia Diseases 0.000 description 9
239000003446 ligand Substances 0.000 description 9
108091008046 non-receptor tyrosine kinases Proteins 0.000 description 9
102000037979 non-receptor tyrosine kinases Human genes 0.000 description 9
230000019491 signal transduction Effects 0.000 description 9
239000012312 sodium hydride Substances 0.000 description 9
229910000104 sodium hydride Inorganic materials 0.000 description 9
230000000638 stimulation Effects 0.000 description 9
239000000725 suspension Substances 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
238000005160 1H NMR spectroscopy Methods 0.000 description 8
108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 8
102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 8
101150028321 Lck gene Proteins 0.000 description 8
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
108700020796 Oncogene Proteins 0.000 description 8
102100038232 Vascular endothelial growth factor C Human genes 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
239000007864 aqueous solution Substances 0.000 description 8
230000004663 cell proliferation Effects 0.000 description 8
238000004891 communication Methods 0.000 description 8
239000002480 mineral oil Substances 0.000 description 8
235000010446 mineral oil Nutrition 0.000 description 8
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 8
210000003491 skin Anatomy 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
239000003826 tablet Substances 0.000 description 8
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 8
239000003981 vehicle Substances 0.000 description 8
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 7
102000003923 Protein Kinase C Human genes 0.000 description 7
108090000315 Protein Kinase C Proteins 0.000 description 7
229920002472 Starch Polymers 0.000 description 7
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 7
150000001413 amino acids Chemical group 0.000 description 7
239000000460 chlorine Substances 0.000 description 7
239000006184 cosolvent Substances 0.000 description 7
230000012010 growth Effects 0.000 description 7
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
229910000041 hydrogen chloride Inorganic materials 0.000 description 7
230000036039 immunity Effects 0.000 description 7
230000001939 inductive effect Effects 0.000 description 7
239000010410 layer Substances 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
239000002773 nucleotide Substances 0.000 description 7
125000003729 nucleotide group Chemical group 0.000 description 7
239000003921 oil Substances 0.000 description 7
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 7
235000015320 potassium carbonate Nutrition 0.000 description 7
239000000843 powder Substances 0.000 description 7
230000009467 reduction Effects 0.000 description 7
238000006722 reduction reaction Methods 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
230000008521 reorganization Effects 0.000 description 7
DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical group CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 7
239000005483 tyrosine kinase inhibitor Substances 0.000 description 7
150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 7
238000009834 vaporization Methods 0.000 description 7
230000008016 vaporization Effects 0.000 description 7
KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
101100503636 Danio rerio fyna gene Proteins 0.000 description 6
108091008794 FGF receptors Proteins 0.000 description 6
101150018272 FYN gene Proteins 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 6
108010002350 Interleukin-2 Proteins 0.000 description 6
102000000588 Interleukin-2 Human genes 0.000 description 6
101150058160 Lyn gene Proteins 0.000 description 6
241000124008 Mammalia Species 0.000 description 6
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 6
108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 6
102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 6
239000004037 angiogenesis inhibitor Substances 0.000 description 6
229940098773 bovine serum albumin Drugs 0.000 description 6
239000002775 capsule Substances 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
238000004440 column chromatography Methods 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
238000001035 drying Methods 0.000 description 6
102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 6
125000002541 furyl group Chemical group 0.000 description 6
239000005457 ice water Substances 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
238000013508 migration Methods 0.000 description 6
CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 description 6
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
238000011160 research Methods 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
239000008107 starch Substances 0.000 description 6
235000019698 starch Nutrition 0.000 description 6
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
241000701447 unidentified baculovirus Species 0.000 description 6
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 5
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
108010057466 NF-kappa B Proteins 0.000 description 5
102000003945 NF-kappa B Human genes 0.000 description 5
206010029113 Neovascularisation Diseases 0.000 description 5
235000008331 Pinus X rigitaeda Nutrition 0.000 description 5
235000011613 Pinus brutia Nutrition 0.000 description 5
241000018646 Pinus brutia Species 0.000 description 5
230000018199 S phase Effects 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
102000013275 Somatomedins Human genes 0.000 description 5
102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 5
108091008605 VEGF receptors Proteins 0.000 description 5
102100038234 Vascular endothelial growth factor D Human genes 0.000 description 5
101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 5
238000010171 animal model Methods 0.000 description 5
239000000872 buffer Substances 0.000 description 5
NWFNSTOSIVLCJA-UHFFFAOYSA-L copper;diacetate;hydrate Chemical compound O.[Cu+2].CC([O-])=O.CC([O-])=O NWFNSTOSIVLCJA-UHFFFAOYSA-L 0.000 description 5
150000004292 cyclic ethers Chemical class 0.000 description 5
GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 5
239000003937 drug carrier Substances 0.000 description 5
210000003725 endotheliocyte Anatomy 0.000 description 5
239000000833 heterodimer Substances 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
230000002209 hydrophobic effect Effects 0.000 description 5
208000026278 immune system disease Diseases 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
239000008101 lactose Substances 0.000 description 5
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
239000000463 material Substances 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
150000004702 methyl esters Chemical class 0.000 description 5
230000005012 migration Effects 0.000 description 5
230000000394 mitotic effect Effects 0.000 description 5
238000002156 mixing Methods 0.000 description 5
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
WWCNXHYRAKUQDB-UHFFFAOYSA-N oxolan-3-yl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1COCC1 WWCNXHYRAKUQDB-UHFFFAOYSA-N 0.000 description 5
239000006187 pill Substances 0.000 description 5
230000002265 prevention Effects 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
230000001737 promoting effect Effects 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
238000012546 transfer Methods 0.000 description 5
238000002054 transplantation Methods 0.000 description 5
230000008728 vascular permeability Effects 0.000 description 5
VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 4
HLCPWBZNUKCSBN-UHFFFAOYSA-N 2-aminobenzonitrile Chemical compound NC1=CC=CC=C1C#N HLCPWBZNUKCSBN-UHFFFAOYSA-N 0.000 description 4
NFSWHYRUVWRUDN-UHFFFAOYSA-N 5-(4-phenoxyphenyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical class C1=2C(N)=NC=NC=2NC=C1C(C=C1)=CC=C1OC1=CC=CC=C1 NFSWHYRUVWRUDN-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
102100034594 Angiopoietin-1 Human genes 0.000 description 4
208000023275 Autoimmune disease Diseases 0.000 description 4
108020004635 Complementary DNA Proteins 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
108010042653 IgA receptor Proteins 0.000 description 4
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
102100035194 Placenta growth factor Human genes 0.000 description 4
229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 4
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
229940121369 angiogenesis inhibitor Drugs 0.000 description 4
235000019445 benzyl alcohol Nutrition 0.000 description 4
230000022131 cell cycle Effects 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
238000001816 cooling Methods 0.000 description 4
238000002425 crystallisation Methods 0.000 description 4
230000008025 crystallization Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
201000002491 encephalomyelitis Diseases 0.000 description 4
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
210000002216 heart Anatomy 0.000 description 4
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000006698 induction Effects 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
231100000682 maximum tolerated dose Toxicity 0.000 description 4
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 4
238000012856 packing Methods 0.000 description 4
229910052763 palladium Inorganic materials 0.000 description 4
230000000737 periodic effect Effects 0.000 description 4
238000012545 processing Methods 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000007789 sealing Methods 0.000 description 4
238000003860 storage Methods 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
239000000829 suppository Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
230000002792 vascular Effects 0.000 description 4
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 3
UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
CBWBJFJMNBPWAL-UHFFFAOYSA-N 4-chloro-5-iodo-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C(I)=CN2 CBWBJFJMNBPWAL-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
102100034608 Angiopoietin-2 Human genes 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
238000011740 C57BL/6 mouse Methods 0.000 description 3
241000283707 Capra Species 0.000 description 3
102000016736 Cyclin Human genes 0.000 description 3
108050006400 Cyclin Proteins 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 3
101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 3
101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 3
101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 3
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 3
208000001132 Osteoporosis Diseases 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
235000003140 Panax quinquefolius Nutrition 0.000 description 3
240000005373 Panax quinquefolius Species 0.000 description 3
108700020978 Proto-Oncogene Proteins 0.000 description 3
102000052575 Proto-Oncogene Human genes 0.000 description 3
108091005682 Receptor kinases Proteins 0.000 description 3
102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 3
102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 3
241000700605 Viruses Species 0.000 description 3
IFQZQDQRHKUYLL-UHFFFAOYSA-N [4-(hydroxymethyl)phenyl]carbamic acid Chemical group OCC1=CC=C(NC(O)=O)C=C1 IFQZQDQRHKUYLL-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 3
201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
238000013019 agitation Methods 0.000 description 3
230000029936 alkylation Effects 0.000 description 3
238000005804 alkylation reaction Methods 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000002917 arthritic effect Effects 0.000 description 3
230000035578 autophosphorylation Effects 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
230000004087 circulation Effects 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
210000000805 cytoplasm Anatomy 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000009849 deactivation Effects 0.000 description 3
230000034994 death Effects 0.000 description 3
238000010511 deprotection reaction Methods 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000001076 estrogenic effect Effects 0.000 description 3
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000011737 fluorine Substances 0.000 description 3
239000006260 foam Substances 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
125000005843 halogen group Chemical group 0.000 description 3
102000058223 human VEGFA Human genes 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000011630 iodine Substances 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
125000000842 isoxazolyl group Chemical group 0.000 description 3
229940043355 kinase inhibitor Drugs 0.000 description 3
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 3
108010052968 leupeptin Proteins 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000006166 lysate Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
239000003757 phosphotransferase inhibitor Substances 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
229920000728 polyester Polymers 0.000 description 3
FKRCODPIKNYEAC-UHFFFAOYSA-N propionic acid ethyl ester Natural products CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
239000000523 sample Substances 0.000 description 3
238000005204 segregation Methods 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
229960001866 silicon dioxide Drugs 0.000 description 3
210000004927 skin cell Anatomy 0.000 description 3
239000012279 sodium borohydride Substances 0.000 description 3
229910000033 sodium borohydride Inorganic materials 0.000 description 3
235000017550 sodium carbonate Nutrition 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
238000000935 solvent evaporation Methods 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
229940095064 tartrate Drugs 0.000 description 3
231100001274 therapeutic index Toxicity 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
UNRBEYYLYRXYCG-UHFFFAOYSA-N (1-ethylpyrrolidin-2-yl)methanamine Chemical compound CCN1CCCC1CN UNRBEYYLYRXYCG-UHFFFAOYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
HJORCZCMNWLHMB-UHFFFAOYSA-N 1-(3-aminopropyl)pyrrolidin-2-one Chemical compound NCCCN1CCCC1=O HJORCZCMNWLHMB-UHFFFAOYSA-N 0.000 description 2
KODLUXHSIZOKTG-UHFFFAOYSA-N 1-aminobutan-2-ol Chemical class CCC(O)CN KODLUXHSIZOKTG-UHFFFAOYSA-N 0.000 description 2
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
GIAFURWZWWWBQT-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanol Chemical compound NCCOCCO GIAFURWZWWWBQT-UHFFFAOYSA-N 0.000 description 2
ZRZOERYTFAWUQQ-UHFFFAOYSA-N 2-(2-aminoethylsulfanyl)ethanol Chemical compound NCCSCCO ZRZOERYTFAWUQQ-UHFFFAOYSA-N 0.000 description 2
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 2
KESZCYFLBJZEPA-UHFFFAOYSA-N 2-fluoro-6-(3-methoxypropylamino)benzonitrile Chemical compound COCCCNC1=CC=CC(F)=C1C#N KESZCYFLBJZEPA-UHFFFAOYSA-N 0.000 description 2
ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 2
HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 2
CJNRGSHEMCMUOE-UHFFFAOYSA-N 2-piperidin-1-ylethanamine Chemical class NCCN1CCCCC1 CJNRGSHEMCMUOE-UHFFFAOYSA-N 0.000 description 2
NAHHNSMHYCLMON-UHFFFAOYSA-N 2-pyridin-3-ylethanamine Chemical compound NCCC1=CC=CN=C1 NAHHNSMHYCLMON-UHFFFAOYSA-N 0.000 description 2
XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-pyridylethylamine Chemical compound NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 description 2
UIKUBYKUYUSRSM-UHFFFAOYSA-N 3-morpholinopropylamine Chemical compound NCCCN1CCOCC1 UIKUBYKUYUSRSM-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
SINQIEAULQKUPD-UHFFFAOYSA-N 4-[4-(6-methoxy-2-naphthalenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine Chemical compound C1=CC2=CC(OC)=CC=C2C=C1C=1N=C(C=2C=CC(=CC=2)S(C)=O)NC=1C1=CC=NC=C1 SINQIEAULQKUPD-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
238000011725 BALB/c mouse Methods 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
CTHYLYWLCPLBHO-UKFGXMPHSA-N C(\C=C/C(=O)O)(=O)O.C(\C=C/C(=O)O)(=O)O.C(\C=C/C(=O)O)(=O)O.C(C1=CC=CC=C1)#N Chemical compound C(\C=C/C(=O)O)(=O)O.C(\C=C/C(=O)O)(=O)O.C(\C=C/C(=O)O)(=O)O.C(C1=CC=CC=C1)#N CTHYLYWLCPLBHO-UKFGXMPHSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
229920000742 Cotton Polymers 0.000 description 2
102000002554 Cyclin A Human genes 0.000 description 2
108010068192 Cyclin A Proteins 0.000 description 2
102000003909 Cyclin E Human genes 0.000 description 2
108090000257 Cyclin E Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
101100372758 Danio rerio vegfaa gene Proteins 0.000 description 2
239000004375 Dextrin Substances 0.000 description 2
229920001353 Dextrin Polymers 0.000 description 2
KGWDUNBJIMUFAP-KVVVOXFISA-N Ethanolamine Oleate Chemical compound NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KGWDUNBJIMUFAP-KVVVOXFISA-N 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
206010015866 Extravasation Diseases 0.000 description 2
102000009465 Growth Factor Receptors Human genes 0.000 description 2
108010009202 Growth Factor Receptors Proteins 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
208000037147 Hypercalcaemia Diseases 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
101150024075 Mapk1 gene Proteins 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 2
101000851005 Mus musculus Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
102000047918 Myelin Basic Human genes 0.000 description 2
101710107068 Myelin basic protein Proteins 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 2
102100028762 Neuropilin-1 Human genes 0.000 description 2
108090000772 Neuropilin-1 Proteins 0.000 description 2
241001597008 Nomeidae Species 0.000 description 2
102000043276 Oncogene Human genes 0.000 description 2
241000700635 Orf virus Species 0.000 description 2
101150093908 PDGFRB gene Proteins 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
206010036049 Polycystic ovaries Diseases 0.000 description 2
101710089165 Protein white Proteins 0.000 description 2
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 2
102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 2
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
108060006706 SRC Proteins 0.000 description 2
102000001332 SRC Human genes 0.000 description 2
206010039361 Sacroiliitis Diseases 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 2
102000002262 Thromboplastin Human genes 0.000 description 2
108010000499 Thromboplastin Proteins 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
101150030763 Vegfa gene Proteins 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
239000000556 agonist Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
239000003513 alkali Substances 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
230000000735 allogeneic effect Effects 0.000 description 2
238000005576 amination reaction Methods 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
239000002870 angiogenesis inducing agent Substances 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000003305 autocrine Effects 0.000 description 2
SJSWRKNSCWKNIR-UHFFFAOYSA-N azane;dihydrochloride Chemical compound N.Cl.Cl SJSWRKNSCWKNIR-UHFFFAOYSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
244000309466 calf Species 0.000 description 2
230000036952 cancer formation Effects 0.000 description 2
125000002837 carbocyclic group Chemical group 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
238000006555 catalytic reaction Methods 0.000 description 2
230000033366 cell cycle process Effects 0.000 description 2
230000006369 cell cycle progression Effects 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000036755 cellular response Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000035605 chemotaxis Effects 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
235000008504 concentrate Nutrition 0.000 description 2
230000003750 conditioning effect Effects 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000005336 cracking Methods 0.000 description 2
239000012043 crude product Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
238000012258 culturing Methods 0.000 description 2
230000006837 decompression Effects 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
230000008021 deposition Effects 0.000 description 2
235000019425 dextrin Nutrition 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 2
ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 2
238000006911 enzymatic reaction Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
210000002744 extracellular matrix Anatomy 0.000 description 2
230000036251 extravasation Effects 0.000 description 2
IHIZJRICNGUMFO-UHFFFAOYSA-N formyl chloride;hydrochloride Chemical compound Cl.ClC=O IHIZJRICNGUMFO-UHFFFAOYSA-N 0.000 description 2
FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
239000003292 glue Substances 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
238000005734 heterodimerization reaction Methods 0.000 description 2
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
229940084986 human chorionic gonadotropin Drugs 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
230000000148 hypercalcaemia Effects 0.000 description 2
208000030915 hypercalcemia disease Diseases 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000009413 insulation Methods 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
235000015110 jellies Nutrition 0.000 description 2
239000008274 jelly Substances 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
238000000021 kinase assay Methods 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
239000002502 liposome Substances 0.000 description 2
210000002751 lymph Anatomy 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
206010025482 malaise Diseases 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
108010082117 matrigel Proteins 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
239000002808 molecular sieve Substances 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
230000002969 morbid Effects 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
QOHMWDJIBGVPIF-UHFFFAOYSA-N n',n'-diethylpropane-1,3-diamine Chemical compound CCN(CC)CCCN QOHMWDJIBGVPIF-UHFFFAOYSA-N 0.000 description 2
QHJABUZHRJTCAR-UHFFFAOYSA-N n'-methylpropane-1,3-diamine Chemical class CNCCCN QHJABUZHRJTCAR-UHFFFAOYSA-N 0.000 description 2
RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 2
CRSOQBOWXPBRES-UHFFFAOYSA-N neopentylidene Natural products CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 description 2
125000006574 non-aromatic ring group Chemical group 0.000 description 2
239000008183 oral pharmaceutical preparation Substances 0.000 description 2
239000003791 organic solvent mixture Substances 0.000 description 2
210000002997 osteoclast Anatomy 0.000 description 2
208000002865 osteopetrosis Diseases 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
150000004866 oxadiazoles Chemical class 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000007170 pathology Effects 0.000 description 2
210000003516 pericardium Anatomy 0.000 description 2
210000004303 peritoneum Anatomy 0.000 description 2
230000035699 permeability Effects 0.000 description 2
239000012466 permeate Substances 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
210000004224 pleura Anatomy 0.000 description 2
201000010065 polycystic ovary syndrome Diseases 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229940068968 polysorbate 80 Drugs 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
238000002203 pretreatment Methods 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
KUYRCJAMEZZYCP-UHFFFAOYSA-N pyridin-3-ylmethyl hydrogen carbonate Chemical group OC(=O)OCC1=CC=CN=C1 KUYRCJAMEZZYCP-UHFFFAOYSA-N 0.000 description 2
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
239000011535 reaction buffer Substances 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
210000000664 rectum Anatomy 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
230000036303 septic shock Effects 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000002511 suppository base Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
239000003104 tissue culture media Substances 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
239000012096 transfection reagent Substances 0.000 description 2
230000014616 translation Effects 0.000 description 2
CCRMAATUKBYMPA-UHFFFAOYSA-N trimethyltin Chemical compound C[Sn](C)C.C[Sn](C)C CCRMAATUKBYMPA-UHFFFAOYSA-N 0.000 description 2
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
238000007738 vacuum evaporation Methods 0.000 description 2
230000006459 vascular development Effects 0.000 description 2
210000003556 vascular endothelial cell Anatomy 0.000 description 2
206010055031 vascular neoplasm Diseases 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000011179 visual inspection Methods 0.000 description 2
210000004885 white matter Anatomy 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
238000002689 xenotransplantation Methods 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
PHBVXHIVWULVNF-UHFFFAOYSA-N (4-fluorophenoxy)boronic acid Chemical compound OB(O)OC1=CC=C(F)C=C1 PHBVXHIVWULVNF-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
125000000355 1,3-benzoxazolyl group Chemical class O1C(=NC2=C1C=CC=C2)* 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
RRQHLOZQFPWDCA-UHFFFAOYSA-N 1-n,1-n-dimethylpropane-1,2-diamine Chemical compound CC(N)CN(C)C RRQHLOZQFPWDCA-UHFFFAOYSA-N 0.000 description 1
GHKCSRZBNZQHKW-UHFFFAOYSA-N 1-sulfanylethanol Chemical class CC(O)S GHKCSRZBNZQHKW-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-UHFFFAOYSA-N 13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3CCC2=C1 VOXZDWNPVJITMN-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 1
JUUBFHLPTCPVBO-UHFFFAOYSA-N 2,2-dimethylpropyl carbonochloridate Chemical compound CC(C)(C)COC(Cl)=O JUUBFHLPTCPVBO-UHFFFAOYSA-N 0.000 description 1
FRUWMYWEARDNTC-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indole Chemical compound C1C=CC=C2NCCC21 FRUWMYWEARDNTC-UHFFFAOYSA-N 0.000 description 1
ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
OJTMHIMQUQOLJV-UHFFFAOYSA-N 2,5-difluorobenzonitrile Chemical compound FC1=CC=C(F)C(C#N)=C1 OJTMHIMQUQOLJV-UHFFFAOYSA-N 0.000 description 1
JFZLDRUSMYBXRI-UHFFFAOYSA-N 2-ethylpyrrolidine Chemical compound CCC1CCCN1 JFZLDRUSMYBXRI-UHFFFAOYSA-N 0.000 description 1
PIVUGOOYGZJRRA-UHFFFAOYSA-N 2-fluoro-6-(2-pyridin-4-ylethylamino)benzonitrile Chemical compound FC1=CC=CC(NCCC=2C=CN=CC=2)=C1C#N PIVUGOOYGZJRRA-UHFFFAOYSA-N 0.000 description 1
HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
WIQRSJOCVVPMPS-UHFFFAOYSA-N 3-(1h-indol-2-yl)pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2NC3=CC=CC=C3C=2)=C1 WIQRSJOCVVPMPS-UHFFFAOYSA-N 0.000 description 1
XUBKRVPXTJMKLB-UHFFFAOYSA-N 3-[4-amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]oxolan-2-one Chemical compound C1=2C(N)=NC=NC=2N(C2C(OCC2)=O)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XUBKRVPXTJMKLB-UHFFFAOYSA-N 0.000 description 1
WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
XDPCNPCKDGQBAN-UHFFFAOYSA-N 3-hydroxytetrahydrofuran Chemical compound OC1CCOC1 XDPCNPCKDGQBAN-UHFFFAOYSA-N 0.000 description 1
KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical class NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 description 1
MFEILWXBDBCWKF-UHFFFAOYSA-N 3-phenylpropanoyl chloride Chemical compound ClC(=O)CCC1=CC=CC=C1 MFEILWXBDBCWKF-UHFFFAOYSA-N 0.000 description 1
MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 1
GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
VSMDINRNYYEDRN-UHFFFAOYSA-N 4-iodophenol Chemical compound OC1=CC=C(I)C=C1 VSMDINRNYYEDRN-UHFFFAOYSA-N 0.000 description 1
KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
PDTHYCGQHARBOW-UHFFFAOYSA-N 6-bromo-5-(4-phenoxyphenyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2NC(Br)=C1C(C=C1)=CC=C1OC1=CC=CC=C1 PDTHYCGQHARBOW-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
206010000605 Acrophobia Diseases 0.000 description 1
208000010370 Adenoviridae Infections Diseases 0.000 description 1
206010060931 Adenovirus infection Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
108010048154 Angiopoietin-1 Proteins 0.000 description 1
108010048036 Angiopoietin-2 Proteins 0.000 description 1
108010009906 Angiopoietins Proteins 0.000 description 1
102000009840 Angiopoietins Human genes 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical class NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 1
201000002909 Aspergillosis Diseases 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
208000036641 Aspergillus infections Diseases 0.000 description 1
KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
241000588807 Bordetella Species 0.000 description 1
101100481403 Bos taurus TIE1 gene Proteins 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
AUABBFXEAKYYOC-UHFFFAOYSA-N C(=C)=C1N=C2N=CC=CC2=C1 Chemical class C(=C)=C1N=C2N=CC=CC2=C1 AUABBFXEAKYYOC-UHFFFAOYSA-N 0.000 description 1
238000011752 CBA/J (JAX™ mouse strain) Methods 0.000 description 1
101150047144 CDC28 gene Proteins 0.000 description 1
241000252983 Caecum Species 0.000 description 1
101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 description 1
235000002566 Capsicum Nutrition 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
208000003732 Cat-scratch disease Diseases 0.000 description 1
102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
208000005590 Choroidal Neovascularization Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
102000002734 Collagen Type VI Human genes 0.000 description 1
108010043741 Collagen Type VI Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
102000003910 Cyclin D Human genes 0.000 description 1
108090000259 Cyclin D Proteins 0.000 description 1
108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
206010012655 Diabetic complications Diseases 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
206010013786 Dry skin Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
210000001956 EPC Anatomy 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
241000792859 Enema Species 0.000 description 1
102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
102000001267 GSK3 Human genes 0.000 description 1
108060006662 GSK3 Proteins 0.000 description 1
YSWHPLCDIMUKFE-QWRGUYRKSA-N Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YSWHPLCDIMUKFE-QWRGUYRKSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
101001005128 Homo sapiens LIM domain kinase 1 Proteins 0.000 description 1
101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020843 Hyperthermia Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102100036433 Interleukin-1 receptor-associated kinase-like 2 Human genes 0.000 description 1
101710182491 Interleukin-1 receptor-associated kinase-like 2 Proteins 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
208000002260 Keloid Diseases 0.000 description 1
206010023330 Keloid scar Diseases 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
102100026023 LIM domain kinase 1 Human genes 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
108010002481 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Proteins 0.000 description 1
102000036243 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Human genes 0.000 description 1
102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
206010025421 Macule Diseases 0.000 description 1
238000006683 Mannich reaction Methods 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000282346 Meles meles Species 0.000 description 1
108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101100323232 Mus musculus Ang3 gene Proteins 0.000 description 1
101100216078 Mus musculus Ang4 gene Proteins 0.000 description 1
101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
PTHRCDREYFGENW-UHFFFAOYSA-N OC(C(=O)O)(C)NC1=CC=CC=C1 Chemical compound OC(C(=O)O)(C)NC1=CC=CC=C1 PTHRCDREYFGENW-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
108091008606 PDGF receptors Proteins 0.000 description 1
229940116355 PI3 kinase inhibitor Drugs 0.000 description 1
206010053869 POEMS syndrome Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
239000006002 Pepper Substances 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
235000016761 Piper aduncum Nutrition 0.000 description 1
235000017804 Piper guineense Nutrition 0.000 description 1
244000203593 Piper nigrum Species 0.000 description 1
235000008184 Piper nigrum Nutrition 0.000 description 1
108010082093 Placenta Growth Factor Proteins 0.000 description 1
208000037062 Polyps Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229920002642 Polysorbate 65 Polymers 0.000 description 1
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
229940078123 Ras inhibitor Drugs 0.000 description 1
101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 1
229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
102000018120 Recombinases Human genes 0.000 description 1
108010091086 Recombinases Proteins 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
206010038933 Retinopathy of prematurity Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241000220317 Rosa Species 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
239000004902 Softening Agent Substances 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
108091082333 TEC family Proteins 0.000 description 1
102000042834 TEC family Human genes 0.000 description 1
240000006474 Theobroma bicolor Species 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
229940124674 VEGF-R inhibitor Drugs 0.000 description 1
UNRBEYYLYRXYCG-SSDOTTSWSA-N [(2r)-1-ethylpyrrolidin-2-yl]methanamine Chemical compound CCN1CCC[C@@H]1CN UNRBEYYLYRXYCG-SSDOTTSWSA-N 0.000 description 1
DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
AFCIMSXHQSIHQW-UHFFFAOYSA-N [O].[P] Chemical compound [O].[P] AFCIMSXHQSIHQW-UHFFFAOYSA-N 0.000 description 1
108700025690 abl Genes Proteins 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
206010069351 acute lung injury Diseases 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
208000011589 adenoviridae infectious disease Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
229940040563 agaric acid Drugs 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000009285 allergic inflammation Effects 0.000 description 1
230000007815 allergy Effects 0.000 description 1
125000006242 amine protecting group Chemical group 0.000 description 1
LHIJANUOQQMGNT-UHFFFAOYSA-N aminoethylethanolamine Chemical compound NCCNCCO LHIJANUOQQMGNT-UHFFFAOYSA-N 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
238000011914 asymmetric synthesis Methods 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000002459 blastocyst Anatomy 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000037058 blood plasma level Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
208000001969 capillary hemangioma Diseases 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
208000003295 carpal tunnel syndrome Diseases 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004534 cecum Anatomy 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
150000005829 chemical entities Chemical class 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
210000003161 choroid Anatomy 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
230000006690 co-activation Effects 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
201000010989 colorectal carcinoma Diseases 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940127113 compound 57 Drugs 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
230000006552 constitutive activation Effects 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
150000001879 copper Chemical class 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
108091008034 costimulatory receptors Proteins 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000013024 dilution buffer Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000004043 dyeing Methods 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000004528 endothelial cell apoptotic process Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
230000010437 erythropoiesis Effects 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
ARFLASKVLJTEJD-UHFFFAOYSA-N ethyl 2-bromopropanoate Chemical compound CCOC(=O)C(C)Br ARFLASKVLJTEJD-UHFFFAOYSA-N 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
239000002038 ethyl acetate fraction Substances 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
LNOQURRKNJKKBU-UHFFFAOYSA-N ethyl piperazine-1-carboxylate Chemical compound CCOC(=O)N1CCNCC1 LNOQURRKNJKKBU-UHFFFAOYSA-N 0.000 description 1
OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
230000003328 fibroblastic effect Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000004992 fission Effects 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000005251 gamma ray Effects 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
238000001030 gas--liquid chromatography Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
125000005908 glyceryl ester group Chemical group 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229920000591 gum Polymers 0.000 description 1
230000002650 habitual effect Effects 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
208000018706 hematopoietic system disease Diseases 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
231100000652 hormesis Toxicity 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000036031 hyperthermia Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000036737 immune function Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000001965 increasing effect Effects 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000012336 iodinating agent Substances 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
230000007794 irritation Effects 0.000 description 1
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
210000001117 keloid Anatomy 0.000 description 1
238000003674 kinase activity assay Methods 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
150000002611 lead compounds Chemical class 0.000 description 1
235000012204 lemonade/lime carbonate Nutrition 0.000 description 1
YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000004460 liquid liquid chromatography Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
244000144972 livestock Species 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
210000002189 macula lutea Anatomy 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000004579 marble Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
125000005905 mesyloxy group Chemical group 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
210000004088 microvessel Anatomy 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
210000004493 neutrocyte Anatomy 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 description 1
108091008819 oncoproteins Proteins 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000004768 organ dysfunction Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000032696 parturition Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
229950000964 pepstatin Drugs 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
150000003053 piperidines Chemical class 0.000 description 1
230000028742 placenta development Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229940012957 plasmin Drugs 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
229940099511 polysorbate 65 Drugs 0.000 description 1
230000026341 positive regulation of angiogenesis Effects 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical class CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
229940080818 propionamide Drugs 0.000 description 1
230000007026 protein scission Effects 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
238000000197 pyrolysis Methods 0.000 description 1
238000012207 quantitative assay Methods 0.000 description 1
125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
239000002994 raw material Substances 0.000 description 1
239000000376 reactant Substances 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
230000000452 restraining effect Effects 0.000 description 1
208000024725 retina neoplasm Diseases 0.000 description 1
238000012552 review Methods 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
238000011808 rodent model Methods 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
150000003346 selenoethers Chemical class 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000011775 sodium fluoride Substances 0.000 description 1
235000013024 sodium fluoride Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000012453 solvate Substances 0.000 description 1
235000014347 soups Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000037351 starvation Effects 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
201000000498 stomach carcinoma Diseases 0.000 description 1
239000004575 stone Substances 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
230000006103 sulfonylation Effects 0.000 description 1
238000005694 sulfonylation reaction Methods 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000003848 thrombocyte activating factor antagonist Substances 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
102000027257 transmembrane receptors Human genes 0.000 description 1
108091008578 transmembrane receptors Proteins 0.000 description 1
230000017105 transposition Effects 0.000 description 1
150000003852 triazoles Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
BPLUKJNHPBNVQL-UHFFFAOYSA-N triphenylarsine Chemical compound C1=CC=CC=C1[As](C=1C=CC=CC=1)C1=CC=CC=C1 BPLUKJNHPBNVQL-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
230000005951 type IV hypersensitivity Effects 0.000 description 1
208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
WQEVDHBJGNOKKO-UHFFFAOYSA-K vanadic acid Chemical compound O[V](O)(O)=O WQEVDHBJGNOKKO-UHFFFAOYSA-K 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
201000009371 venous hemangioma Diseases 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1
229910000166 zirconium phosphate Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
AIDS & HIV (AREA)
Obesity (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Tropical Medicine & Parasitology (AREA)

CN99813217A 1998-09-18 1999-09-17 作为蛋白激酶抑制剂的吡咯并嘧啶 Pending CN1335849A (zh)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date
US10083498P	1998-09-18	1998-09-18
US10083398P	1998-09-18	1998-09-18
US10083298P	1998-09-18	1998-09-18
US10094698P	1998-09-18	1998-09-18
US60/100,834		1998-09-18
US60/100,833		1998-09-18
US60/100,946		1998-09-18
US60/100,832		1998-09-18

Publications (1)

Publication Number	Publication Date
CN1335849A true CN1335849A (zh)	2002-02-13

Family

ID=27493158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN99813217A Pending CN1335849A (zh)	1998-09-18	1999-09-17	作为蛋白激酶抑制剂的吡咯并嘧啶

Country Status (19)

Country	Link
EP (1)	EP1114053A1 (ko)
JP (1)	JP2002526500A (ko)
KR (1)	KR20010085824A (ko)
CN (1)	CN1335849A (ko)
AU (1)	AU753555C (ko)
BG (1)	BG105346A (ko)
BR (1)	BR9913887A (ko)
CA (1)	CA2344249A1 (ko)
CZ (1)	CZ2001960A3 (ko)
HK (1)	HK1039326A1 (ko)
HU (1)	HUP0200403A3 (ko)
ID (1)	ID29028A (ko)
IL (1)	IL141866A0 (ko)
NO (1)	NO20011356L (ko)
NZ (1)	NZ510588A (ko)
PL (1)	PL346700A1 (ko)
SK (1)	SK3842001A3 (ko)
TR (1)	TR200101186T2 (ko)
WO (1)	WO2000017203A1 (ko)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100439365C (zh) *	2003-08-28	2008-12-03	Irm责任有限公司	用作蛋白激酶抑制剂的化合物和组合物
CN102007125B (zh) *	2008-01-15	2016-05-25	安姆根有限公司	稠合杂环衍生物及使用方法
CN105829313A (zh) *	2013-11-19	2016-08-03	制药科学公司	蛋白激酶抑制剂
CN112961158A (zh) *	2020-03-05	2021-06-15	四川大学华西医院	氨基嘧啶并吡唑/吡咯类衍生物及其制备方法和用途
CN112961159A (zh) *	2020-03-05	2021-06-15	四川大学华西医院	氨基嘧啶并吡唑/吡咯类衍生物及其制备方法和用途
WO2024008128A1 (zh) *	2022-07-06	2024-01-11	上海科恩泰生物医药科技有限公司	一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
ES2274634T3 (es)	1998-08-29	2007-05-16	Astrazeneca Ab	Compuestos de pirimidina.
ES2270612T3 (es)	1998-08-29	2007-04-01	Astrazeneca Ab	Compuestos de pirimidina.
US6713474B2 (en)	1998-09-18	2004-03-30	Abbott Gmbh & Co. Kg	Pyrrolopyrimidines as therapeutic agents
GB9828511D0 (en)	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
GB9905075D0 (en)	1999-03-06	1999-04-28	Zeneca Ltd	Chemical compounds
GB9907658D0 (en)	1999-04-06	1999-05-26	Zeneca Ltd	Chemical compounds
GB9919778D0 (en)	1999-08-21	1999-10-27	Zeneca Ltd	Chemical compounds
MXPA02005675A (es)	1999-12-10	2002-09-02	Pfizer Prod Inc	Compuestos de pirrolo(2,3-d)pirimidina.
CA2397575A1 (en) *	2000-01-13	2001-07-19	Tularik Inc.	Antibacterial agents
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004888D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004887D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004886D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0007371D0 (en)	2000-03-28	2000-05-17	Astrazeneca Uk Ltd	Chemical compounds
WO2001072751A1 (en) *	2000-03-29	2001-10-04	Knoll Gesellschaft Mit Beschraenkter Haftung	Pyrrolopyrimidines as tyrosine kinase inhibitors
US7369946B2 (en)	2000-03-29	2008-05-06	Abbott Gmbh & Co. Kg	Method of identifying inhibitors of Tie-2
DK1294724T3 (da) *	2000-06-26	2006-07-17	Pfizer Prod Inc	Pyrrolo[2,3-d]pyrimidinforbindelser som immunosuppresive midler
GB0016877D0 (en)	2000-07-11	2000-08-30	Astrazeneca Ab	Chemical compounds
GB0103926D0 (en)	2001-02-17	2001-04-04	Astrazeneca Ab	Chemical compounds
US7081454B2 (en)	2001-03-28	2006-07-25	Bristol-Myers Squibb Co.	Tyrosine kinase inhibitors
TWI238824B (en)	2001-05-14	2005-09-01	Novartis Ag	4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
GB0113041D0 (en)	2001-05-30	2001-07-18	Astrazeneca Ab	Chemical compounds
GB0121033D0 (en) *	2001-08-30	2001-10-24	Novartis Ag	Organic compounds
GB0205690D0 (en)	2002-03-09	2002-04-24	Astrazeneca Ab	Chemical compounds
GB0205688D0 (en)	2002-03-09	2002-04-24	Astrazeneca Ab	Chemical compounds
GB0205693D0 (en)	2002-03-09	2002-04-24	Astrazeneca Ab	Chemical compounds
US7442697B2 (en)	2002-03-09	2008-10-28	Astrazeneca Ab	4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
BR0313078A (pt)	2002-08-06	2005-07-12	Astrazeneca Ab	Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou de um sal deste farmaceuticamente aceitável
GB0226370D0 (en) *	2002-11-12	2002-12-18	Novartis Ag	Organic compounds
NZ539901A (en)	2002-11-26	2007-09-28	Pfizer Prod Inc	Method of treatment of transplant rejection
UA80171C2 (en)	2002-12-19	2007-08-27	Pfizer Prod Inc	Pyrrolopyrimidine derivatives
BRPI0408248A (pt)	2003-03-12	2006-03-01	Pfizer Prod Inc	derivados azabicìclicos de piridiloximetila e de benzisoxazol
GB0311274D0 (en)	2003-05-16	2003-06-18	Astrazeneca Ab	Chemical compounds
GB0311276D0 (en)	2003-05-16	2003-06-18	Astrazeneca Ab	Chemical compounds
AR045037A1 (es)	2003-07-10	2005-10-12	Aventis Pharma Sa	Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
US7312215B2 (en)	2003-07-29	2007-12-25	Bristol-Myers Squibb Company	Benzimidazole C-2 heterocycles as kinase inhibitors
JP2007511596A (ja) *	2003-11-17	2007-05-10	ファイザー・プロダクツ・インク	癌の治療において有用なピロロピリミジン化合物
TW200528101A (en)	2004-02-03	2005-09-01	Astrazeneca Ab	Chemical compounds
JP2007520559A (ja) *	2004-02-03	2007-07-26	アボット・ラボラトリーズ	治療薬としてのアミノベンゾオキサゾール類
MXPA06011423A (es)	2004-04-02	2007-01-23	Osi Pharm Inc	Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
WO2005116035A1 (en)	2004-05-27	2005-12-08	Pfizer Products Inc.	Pyrrolopyrimidine derivatives useful in cancer treatment
MY139689A (en)	2004-07-20	2009-10-30	Osi Pharm Inc	Imidazotriazines as protein kinase inhibitors
PE20060748A1 (es) *	2004-09-21	2006-10-01	Smithkline Beecham Corp	Derivados de indolcarboxamida como inhibidores de quinasa ikk2
MX2007011435A (es) *	2005-03-17	2007-12-05	Novartis Ag	N-[3-(1-amino-5,6,7,8-tetrahidro-2,4,4b-triazafluoren-9-il)-fenil ]-benzamidas como inhibidores de cinasa de tirosina/treonina, en particular de cinasa b-raf.
WO2006114180A1 (de) *	2005-04-25	2006-11-02	Merck Patent Gmbh	Neuartige aza-heterozyklen als kinase-inhibitoren
ATE533057T1 (de)	2005-09-20	2011-11-15	Osi Pharm Inc	Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
JP2009512636A (ja)	2005-09-30	2009-03-26	アストラゼネカアクチボラグ	細胞増殖抑制作用を有するイミダゾ［１，２−ａ］ピリジン類
US8431695B2 (en)	2005-11-02	2013-04-30	Bayer Intellectual Property Gmbh	Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
AR057960A1 (es)	2005-12-02	2007-12-26	Osi Pharm Inc	Inhibidores de proteina quinasa biciclicos
WO2007095223A2 (en) *	2006-02-14	2007-08-23	Vertex Pharmaceuticals Incorporated	Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
RS20080525A (en)	2006-05-09	2009-09-08	Pfizer Products Inc.,	Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
US20100190777A1 (en)	2007-07-17	2010-07-29	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
JP4884570B2 (ja)	2008-08-20	2012-02-29	ファイザー・インク	ピロロ［２，３−ｄ］ピリミジン化合物
JP5819195B2 (ja) *	2008-10-16	2015-11-18	ザリージェンツオブザユニバーシティオブカリフォルニア	融合環ヘテロアリールキナーゼ阻害剤
CA2742986C (en)	2008-11-07	2015-03-31	Triact Therapeutics, Inc.	Use of catecholic butane derivatives in cancer therapy
EP2390254A1 (en) *	2009-01-22	2011-11-30	Mitsubishi Tanabe Pharma Corporation	NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND
EP2400985A2 (en)	2009-02-25	2012-01-04	OSI Pharmaceuticals, LLC	Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
WO2010099137A2 (en)	2009-02-26	2010-09-02	Osi Pharmaceuticals, Inc.	In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401613A2 (en)	2009-02-27	2012-01-04	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en)	2009-02-27	2012-01-04	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2424368B1 (en) *	2009-04-29	2014-12-31	Locus Pharmaceuticals, Inc.	Pyrrolotriazine compounds
US7718662B1 (en) *	2009-10-12	2010-05-18	Pharmacyclics, Inc.	Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
JP2013527748A (ja)	2010-03-03	2013-07-04	オーエスアイ・ファーマシューティカルズ，エルエルシー	インスリン様増殖因子１受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー
CA2783665A1 (en)	2010-03-03	2011-09-09	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP2013522215A (ja)	2010-03-09	2013-06-13	オーエスアイ・ファーマシューティカルズ，エルエルシー	組合わせ抗癌療法
WO2012116040A1 (en)	2011-02-22	2012-08-30	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2683722A1 (en) *	2011-03-08	2014-01-15	Novartis AG	Fluorophenyl bicyclic heteroaryl compounds
EP2702173A1 (en)	2011-04-25	2014-03-05	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EA201490265A1 (ru)	2011-07-13	2014-12-30	Фармасайкликс, Инк.	Ингибиторы тирозинкиназы брутона
LT2734522T (lt)	2011-07-19	2019-02-11	Merck Sharp & Dohme B.V.	4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk-inhibitoriai
MX370814B (es)	2011-09-02	2020-01-08	Univ California	Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US8377946B1 (en)	2011-12-30	2013-02-19	Pharmacyclics, Inc.	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
JP5985658B2 (ja) *	2012-01-31	2016-09-06	ナンジンアルゲンファルマカンパニーリミテッドＮａｎｊｉｎｇＡｌｌｇｅｎＰｈａｒｍａＣｏ．Ｌｔｄ．	ブルトンチロシンキナーゼ阻害薬としての環状分子
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
JP6327713B2 (ja) *	2012-07-27	2018-05-23	国立研究開発法人理化学研究所	急性骨髄性白血病の治療又は再発抑制剤
BR112015006828A8 (pt)	2012-09-26	2019-09-17	Univ California	composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
EP2961412A4 (en)	2013-02-26	2016-11-09	Triact Therapeutics Inc	CANCER THERAPY
WO2015035410A1 (en)	2013-09-09	2015-03-12	Triact Therapeutic, Inc.	Cancer therapy
BR112016006978A2 (pt)	2013-09-30	2017-08-01	Pharmacyclics Llc	inibidores de tirosina quinase de bruton
WO2015068767A1 (ja)	2013-11-08	2015-05-14	小野薬品工業株式会社	ピロロピリミジン誘導体
CA2834528A1 (en) *	2013-11-26	2015-05-26	Pharmascience Inc.	Protein kinase inhibitors
US9840509B2 (en)	2014-02-03	2017-12-12	Cadila Healthcare Limited	Heterocyclic compounds
EP3179991B1 (en)	2014-08-11	2021-10-06	Acerta Pharma B.V.	Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
AU2016365400C1 (en) *	2015-12-02	2022-11-10	Astraea Therapeutics, Llc	Piperidinyl nociceptin receptor compounds
US10112924B2 (en)	2015-12-02	2018-10-30	Astraea Therapeutics, Inc.	Piperdinyl nociceptin receptor compounds
KR20210057014A (ko) *	2018-09-13	2021-05-20	깃세이 야쿠힌 고교 가부시키가이샤	이미다조피리디논 화합물
WO2021038540A1 (en)	2019-08-31	2021-03-04	Sun Pharma Advanced Research Company Limited	Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
BR112022006977A2 (pt) *	2019-10-11	2022-09-20	Incyte Corp	Aminas bicíclicas como inibidores de cdk2
US11981671B2 (en)	2021-06-21	2024-05-14	Incyte Corporation	Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en)	2021-12-10	2024-05-07	Incyte Corporation	Bicyclic amines as CDK2 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3036390A1 (de) *	1980-09-26	1982-05-13	Troponwerke GmbH & Co KG, 5000 Köln	Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen
CA2100863A1 (en) *	1991-01-23	1992-07-24	David A. Bullough	Adenosine kinase inhibitors
IL108523A0 (en) *	1993-02-03	1994-05-30	Gensia Inc	Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
PT783505E (pt) *	1994-09-29	2001-08-30	Novartis Ag	Pirrolo¬2,3-d\|pirimidinas e sua utilizacao
US6143749A (en) *	1995-06-07	2000-11-07	Abbott Laboratories	Heterocyclic substituted cyclopentane compounds
US5665721A (en) *	1995-06-07	1997-09-09	Abbott Laboratories	Heterocyclic substituted cyclopentane compounds
CH690773A5 (de) *	1996-02-01	2001-01-15	Novartis Ag	Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
AU1794697A (en) *	1996-03-06	1997-09-22	Novartis Ag	7-alkyl-pyrrolo{2,3-d}pyrimidines
KR20000064601A (ko) *	1996-03-15	2000-11-06	한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터	신규의n-7-헤테로시클릴피롤로[2,3-d]피리딘및�그의용도
WO1998041525A1 (en) *	1997-03-19	1998-09-24	Basf Aktiengesellschaft	Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors

1999
- 1999-09-17 ID IDW20010652A patent/ID29028A/id unknown
- 1999-09-17 TR TR2001/01186T patent/TR200101186T2/xx unknown
- 1999-09-17 JP JP2000574112A patent/JP2002526500A/ja active Pending
- 1999-09-17 CA CA002344249A patent/CA2344249A1/en not_active Abandoned
- 1999-09-17 IL IL14186699A patent/IL141866A0/xx unknown
- 1999-09-17 SK SK384-2001A patent/SK3842001A3/sk unknown
- 1999-09-17 EP EP99969415A patent/EP1114053A1/en not_active Withdrawn
- 1999-09-17 KR KR1020017003532A patent/KR20010085824A/ko not_active Application Discontinuation
- 1999-09-17 PL PL99346700A patent/PL346700A1/xx unknown
- 1999-09-17 CN CN99813217A patent/CN1335849A/zh active Pending
- 1999-09-17 CZ CZ2001960A patent/CZ2001960A3/cs unknown
- 1999-09-17 HU HU0200403A patent/HUP0200403A3/hu unknown
- 1999-09-17 BR BR9913887-5A patent/BR9913887A/pt not_active IP Right Cessation
- 1999-09-17 AU AU60484/99A patent/AU753555C/en not_active Ceased
- 1999-09-17 WO PCT/US1999/021560 patent/WO2000017203A1/en not_active Application Discontinuation
- 1999-09-17 NZ NZ510588A patent/NZ510588A/en unknown
2001
- 2001-03-15 BG BG105346A patent/BG105346A/xx unknown
- 2001-03-16 NO NO20011356A patent/NO20011356L/no not_active Application Discontinuation
2002
- 2002-01-11 HK HK02100227.3A patent/HK1039326A1/zh unknown

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100439365C (zh) *	2003-08-28	2008-12-03	Irm责任有限公司	用作蛋白激酶抑制剂的化合物和组合物
CN102007125B (zh) *	2008-01-15	2016-05-25	安姆根有限公司	稠合杂环衍生物及使用方法
CN105829313A (zh) *	2013-11-19	2016-08-03	制药科学公司	蛋白激酶抑制剂
CN112961158A (zh) *	2020-03-05	2021-06-15	四川大学华西医院	氨基嘧啶并吡唑/吡咯类衍生物及其制备方法和用途
CN112961159A (zh) *	2020-03-05	2021-06-15	四川大学华西医院	氨基嘧啶并吡唑/吡咯类衍生物及其制备方法和用途
CN112961158B (zh) *	2020-03-05	2022-07-01	四川大学华西医院	氨基嘧啶并吡唑/吡咯类衍生物及其制备方法和用途
WO2024008128A1 (zh) *	2022-07-06	2024-01-11	上海科恩泰生物医药科技有限公司	一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途

Also Published As

Publication number	Publication date
HUP0200403A2 (en)	2002-06-29
KR20010085824A (ko)	2001-09-07
NZ510588A (en)	2003-08-29
HK1039326A1 (zh)	2002-04-19
IL141866A0 (en)	2002-03-10
AU6048499A (en)	2000-04-10
EP1114053A1 (en)	2001-07-11
JP2002526500A (ja)	2002-08-20
WO2000017203A1 (en)	2000-03-30
CZ2001960A3 (cs)	2001-10-17
AU753555C (en)	2003-07-03
NO20011356D0 (no)	2001-03-16
ID29028A (id)	2001-07-26
TR200101186T2 (tr)	2001-10-22
AU753555B2 (en)	2002-10-24
PL346700A1 (en)	2002-02-25
CA2344249A1 (en)	2000-03-30
BG105346A (en)	2001-12-29
NO20011356L (no)	2001-05-16
SK3842001A3 (en)	2002-04-04
BR9913887A (pt)	2001-10-23
HUP0200403A3 (en)	2004-07-28

Legal Events

Date	Code	Title	Description
2002-02-13	C06	Publication
2002-02-13	C10	Entry into substantive examination
2002-02-13	PB01	Publication
2002-02-13	SE01	Entry into force of request for substantive examination
2003-10-08	ASS	Succession or assignment of patent right	Owner name: AVECIA BIOLOGY TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: BASF AKTIENGESELLCHAFT Effective date: 20030814
2003-10-08	C41	Transfer of patent application or patent right or utility model
2003-10-08	TA01	Transfer of patent application right	Effective date of registration: 20030814 Address after: Wiesbaden Applicant after: Ebert GmbH & Co. KG Address before: Ludwigshafen, Germany Applicant before: Basf AG
2006-07-26	C02	Deemed withdrawal of patent application after publication (patent law 2001)
2006-07-26	WD01	Invention patent application deemed withdrawn after publication

Publication	Publication Date	Title
CN1335849A (zh)	2002-02-13	作为蛋白激酶抑制剂的吡咯并嘧啶
CN1390220A (zh)	2003-01-08	作为治疗剂的激酶抑制剂
CN1422262A (zh)	2003-06-04	2－苯并噻唑基脲衍生物及其作为蛋白激酶抑制剂的应用
CN1193026C (zh)	2005-03-16	2－吡唑啉－5－酮
CN1326457A (zh)	2001-12-12	作为激酶抑制剂的4－氨基吡咯并嘧啶
CN1134439C (zh)	2004-01-14	吡咯并[2,3d]嘧啶类化合物及它们作为酪氨酸激酶抑制剂的用途
US10463675B2 (en)	2019-11-05	Aminopyrimidinyl compounds
JP4707167B2 (ja)	2011-06-22	キナーゼ阻害剤
CN1636005A (zh)	2005-07-06	苯并噻嗪酮和苯并噁嗪酮化合物
CN1335836A (zh)	2002-02-13	三环吡唑衍生物
CN1149196C (zh)	2004-05-12	作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺
CN1520298A (zh)	2004-08-11	作为治疗剂的吡唑并嘧啶类
CN1252067C (zh)	2006-04-19	吲哚衍生物及其作为jnk调节剂的应用
US9815841B2 (en)	2017-11-14	Compounds
CN1390219A (zh)	2003-01-08	作为治疗剂的吡唑并嘧啶类
CN1809576A (zh)	2006-07-26	抗寄生物萜类生物碱
CN1678372A (zh)	2005-10-05	用作生长激素促分泌素的杂环芳香化合物
CN1671711A (zh)	2005-09-21	降钙素基因相关肽受体拮抗剂
CN1500080A (zh)	2004-05-26	稠合杂环化合物
CN1439009A (zh)	2003-08-27	咪唑并嘧啶衍生物和***并嘧啶衍生物
CN1582277A (zh)	2005-02-16	用作糖原合酶激酶3β抑制剂的酰胺衍生物
CN1284948A (zh)	2001-02-21	治疗活性化合物中的儿茶酚的吲唑生物等排物置换
CN101426792A (zh)	2009-05-06	作为治疗剂的吡唑并嘧啶类
CN1278794A (zh)	2001-01-03	用作蛋白酪氨酸激酶和蛋白丝氨酸/苏氨酸激酶抑制剂的取代的2－羟基吲哚衍生物
CN1496257A (zh)	2004-05-12	调控免疫球蛋白e及抑制细胞增殖的苯并咪唑化合物